1351522-05-8 Usage
General Description
AC-710 Mesylate is a chemical compound that belongs to a class of non-steroidal anti-inflammatory drugs known as coxib inhibitors. It acts as a selective inhibitor of cyclooxygenase-2 (COX-2) enzyme, which is responsible for the production of prostaglandins that cause inflammation and pain. AC-710 Mesylate is being studied for its potential use in the treatment of chronic pain conditions, such as osteoarthritis and rheumatoid arthritis. It has shown promising results in preclinical studies by effectively reducing inflammation and pain without causing gastrointestinal side effects commonly associated with non-selective COX inhibitors. Additionally, AC-710 Mesylate has demonstrated potential neuroprotective and anti-tumor properties in animal studies, suggesting its potential for broader therapeutic applications. However, further clinical trials are needed to fully understand its safety and efficacy in humans.
Check Digit Verification of cas no
The CAS Registry Mumber 1351522-05-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,1,5,2 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1351522-05:
(9*1)+(8*3)+(7*5)+(6*1)+(5*5)+(4*2)+(3*2)+(2*0)+(1*5)=118
118 % 10 = 8
So 1351522-05-8 is a valid CAS Registry Number.
1351522-05-8Relevant articles and documents
Discovery of AC710, a globally selective inhibitor of platelet-derived growth factor receptor-family kinases
Liu, Gang,Campbell, Brian T.,Holladay, Mark W.,Ford Pulido, Julia M.,Hua, Helen,Gitnick, Dana,Gardner, Michael F.,James, Joyce,Breider, Mike A.,Brigham, Daniel,Belli, Barbara,Armstrong, Robert C.,Treiber, Daniel K.
, p. 997 - 1002 (2013/02/23)
A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacokinetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the α-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.
